Sareum (LON:SAR) Releases Earnings Results

Sareum (LON:SAR) issued its earnings results on Thursday. The company reported GBX (1.20) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Sareum Price Performance

LON:SAR opened at GBX 14.36 on Thursday. The firm has a 50-day moving average of GBX 17.44 and a 200-day moving average of GBX 17.62. The company has a market cap of £19.83 million, a PE ratio of -3.99 and a beta of -1.08. Sareum has a one year low of GBX 9.50 and a one year high of GBX 29.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.